Characterization and real-live results of nebulized voriconazole: A single-center observational study

Pulmonary administration of voriconazole involves advantages, including optimization of lung penetration and reduction of adverse effects and interactions. However, there is scarce evidence about its use and there are no commercial presentations for nebulization. We aim to characterize a compounded...

Full description

Saved in:
Bibliographic Details
Published inFarmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria Vol. 48; no. 1; p. T29
Main Authors Larrosa-Garcia, Maria, Terradas Campanario, Sònia, Fernández Polo, Aurora, Cañete Ramírez, Carme, Parra, Alba Pau, Campany Herrero, David
Format Journal Article
LanguageEnglish
Published Spain 01.01.2024
Subjects
Administration, Intravenous
Adult
Antifungal Agents - adverse effects
Child
Drug-Related Side Effects and Adverse Reactions
Humans
Lung Diseases, Fungal
Retrospective Studies
Voriconazole - adverse effects
Fungal lung disease
Formulación magistral
Compounding
Enfermedad pulmonar fúngica
Aspergillosis
Voriconazol
Voriconazole
Nebulizer
Aspergilosis
Nebulizador
Online AccessGet more information

Cover

More Information
Summary:Pulmonary administration of voriconazole involves advantages, including optimization of lung penetration and reduction of adverse effects and interactions. However, there is scarce evidence about its use and there are no commercial presentations for nebulization. We aim to characterize a compounded voriconazole solution for nebulization and describe its use in our center. This is a retrospective observational study including patients who received nebulized voriconazole to treat fungal lung diseases (infection or colonization). Voriconazole solution was prepared from commercial vials for intravenous administration. The pH and osmolarity of voriconazole solutions were adequate for nebulization. Ten patients were included, nine adults and a child. The dosage was 40 mg in adults and 10 mg in the pediatric patient, diluted to a final concentration of 10 mg/ml, administered every 12-24 hours. The median duration of treatment was 139 (range: 26-911) days. There were no reported adverse effects and the drug was not detected in plasma when nebulized only. Voriconazole nebulization is well tolerated and it is not absorbed into the systemic circulation; further research is needed to assess its efficacy.
ISSN:2171-8695